FRTX Stock Overview
Does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Fresh Tracks Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.74 |
| 52 Week High | US$1.03 |
| 52 Week Low | US$0.55 |
| Beta | 0.53 |
| 1 Month Change | 3.85% |
| 3 Month Change | -1.00% |
| 1 Year Change | -7.19% |
| 3 Year Change | -93.29% |
| 5 Year Change | -98.92% |
| Change since IPO | -99.65% |
Recent News & Updates
Recent updates
Brickell Biotech changes name to Fresh Tracks Therapeutics
Sep 07Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M
Aug 11Brickell Biotech regains Nasdaq compliance for minimum bid price requirement
Jul 20Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely
Feb 14
Brickell Biotech Advances To Phase III As It Eyes Commercialization
May 10Brickell Biotech completes patient enrollment in late-stage sweat disorder study
Apr 27Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.
Jan 06
Brickell Biotech (BBI) Investor Presentation - Slideshow
Dec 02Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26
Nov 18Shareholder Returns
| FRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.0% | -3.3% | -2.2% |
| 1Y | -7.2% | -1.9% | 23.9% |
Return vs Industry: FRTX underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: FRTX underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| FRTX volatility | |
|---|---|
| FRTX Average Weekly Movement | 2.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FRTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FRTX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 4 | Bert Marchio | ir.frtx.com |
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Fresh Tracks Therapeutics, Inc. Fundamentals Summary
| FRTX fundamental statistics | |
|---|---|
| Market cap | US$4.42m |
| Earnings (TTM) | -US$5.69m |
| Revenue (TTM) | US$8.01m |
0.6x
P/S Ratio-0.8x
P/E RatioIs FRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRTX income statement (TTM) | |
|---|---|
| Revenue | US$8.01m |
| Cost of Revenue | US$3.18m |
| Gross Profit | US$4.82m |
| Other Expenses | US$10.52m |
| Earnings | -US$5.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 60.25% |
| Net Profit Margin | -71.12% |
| Debt/Equity Ratio | 0% |
How did FRTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:35 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fresh Tracks Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Thomas Flaten | Lake Street Capital Markets, LLC |
| Leland Gershell | Oppenheimer & Co. Inc. |